Spire Wealth Management Annovis Bio, Inc. Transaction History

Spire Wealth Management

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Jan 14, 2022	SELL	$17.58 - $37.67 $5,449 - $11,677	-310 Closed	0 $0
Q3 2021 Oct 22, 2021	SELL	$30.95 - $120.97 $13,772 - $53,831	-445 Reduced 58.94%	310 $10,000
Q2 2021 Jul 26, 2021	SELL	$21.55 - $96.1 $5,279 - $23,544	-245 Reduced 24.5%	755 $65,000
Q1 2021 May 21, 2021	BUY	$8.15 - $38.44 $8,150 - $38,440	1,000 New	1,000 $28,000

1.17M

229K

934K

Ticker ANVS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 8,163,920
Market Cap $44M
Description
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...

Get notified when there are updates to the investment portfolio of Spire Wealth Management, based on Form 13F filings with the SEC.

Stay updated on Spire Wealth Management with notifications on news.